<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD03490000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q16539</UniProt_ID>
  <Seq_Length>360</Seq_Length>
  <Molecule_Weight>41293</Molecule_Weight>
  <KEGG_ID>hsa:1432</KEGG_ID>
  <Orthology_ID>K04441</Orthology_ID>
  <EBI_ID>EBI-73946</EBI_ID>
  <Function_Summary>Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additionnal targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery. On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2. MAPK14 interacts also with casein kinase II, leading to its activation through autophosphorylation and further phosphorylation of TP53/p53. In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. In a similar way, MAPK14 phosphorylates the ubiquitin ligase SIAH2, regulating its activity towards EGLN3. MAPK14 may also inhibit the lysosomal degradation pathway of autophagy by interfering with the intracellular trafficking of the transmembrane protein ATG9. Another function of MAPK14 is to regulate the endocytosis of membrane receptors by different mechanisms that impinge on the small GTPase RAB5A. In addition, clathrin-mediated EGFR internalization induced by inflammatory cytokines and UV irradiation depends on MAPK14-mediated phosphorylation of EGFR itself as well as of RAB5A effectors. Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Another p38 MAPK substrate is FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment. Phosphorylates CDC25B and CDC25C which is required for binding to 14-3-3 proteins and leads to initiation of a G2 delay after ultraviolet radiation. Phosphorylates TIAR following DNA damage, releasing TIAR from GADD45A mRNA and preventing mRNA degradation. The p38 MAPKs may also have kinase-independent roles, which are thought to be due to the binding to targets in the absence of phosphorylation. Protein O-Glc-N-acylation catalyzed by the OGT is regulated by MAPK14, and, although OGT does not seem to be phosphorylated by MAPK14, their interaction increases upon MAPK14 activation induced by glucose deprivation. This interaction may regulate OGT activity by recruiting it to specific targets such as neurofilament H, stimulating its O-Glc-N-acylation. Required in mid-fetal development for the growth of embryo-derived blood vessels in the labyrinth layer of the placenta. Also plays an essential role in developmental and stress-induced erythropoiesis, through regulation of EPO gene expression. Isoform MXI2 activation is stimulated by mitogens and oxidative stress and only poorly phosphorylates ELK1 and ATF2. Isoform EXIP may play a role in the early onset of apoptosis.</Function_Summary>
  <Catalytic_Mechanism>ATP + a protein = ADP + a phosphoprotein.</Catalytic_Mechanism>
  <Pfam_ID>PF00069:Pkinase</Pfam_ID>
  <Allosteric_Activator_Count>3</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>85</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>69</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>CSAID-binding protein</Alias>
      <Alias>MAX-interacting protein 2</Alias>
      <Alias>SAPK2A</Alias>
      <Alias>Stress-activated protein kinase 2A</Alias>
      <Alias>CSBP</Alias>
      <Alias>Cytokine suppressive anti-inflammatory drug binding protein</Alias>
      <Alias>MAPK 14</Alias>
      <Alias>P38 MAP kinase</Alias>
      <Alias>P38 mitogen activated protein kinase</Alias>
      <Alias>MAP kinase p38 alpha</Alias>
      <Alias>Mitogen-activated protein kinase p38 alpha</Alias>
      <Alias>MAP kinase 14</Alias>
      <Alias>MAP kinase Mxi2</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with NFAT (nuclear factor of activated T cells) proteins, a family of transcription factors. NFAT proteins have crucial roles in the development and function of the immune system.</Detail>
      <Keyword>NFAT protein binding</Keyword>
      <Ontology_ID>GO:0051525</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reactions: ATP + protein serine = ADP + protein serine phosphate, and ATP + protein threonine = ADP + protein threonine phosphate.</Detail>
      <Keyword>Protein serine/threonine kinase activity</Keyword>
      <Ontology_ID>GO:0004674</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: protein + ATP = protein phosphate + ADP. This reaction is the phosphorylation of proteins. Mitogen-activated protein kinase; a family of protein kinases that perform a crucial step in relaying signals from the plasma membrane to the nucleus. They are activated by a wide range of proliferation- or differentiation-inducing signals; activation is strong with agonists such as polypeptide growth factors and tumor-promoting phorbol esters, but weak (in most cell backgrounds) by stress stimuli.</Detail>
      <Keyword>MAP kinase activity</Keyword>
      <Ontology_ID>GO:0004707</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the concomitant phosphorylation of threonine (T) and tyrosine (Y) residues in a Thr-Glu-Tyr (TEY) thiolester sequence in MAP kinases. It is a dual-specificity mitogen-activated protein kinase kinase and requires activation by the serine/threonine kinase, MAP kinase kinase kinase.</Detail>
      <Keyword>MAP kinase kinase activity</Keyword>
      <Ontology_ID>GO:0004708</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>322</Position>
      <Original>Pro</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>51</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>343</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of muscle cell differentiation.</Detail>
      <Keyword>Positive regulation of muscle cell differentiation</Keyword>
      <Ontology_ID>GO:0051149</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to a toll-like receptor where the TRIF adaptor mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response.</Detail>
      <Keyword>TRIF-dependent toll-like receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0035666</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals initiated by binding of an extracellular ligand to the Toll receptor on the surface of the target cell.</Detail>
      <Keyword>Toll signaling pathway</Keyword>
      <Ontology_ID>GO:0008063</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of vascular endothelial growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Vascular endothelial growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0048010</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 1.</Detail>
      <Keyword>Toll-like receptor 1 signaling pathway</Keyword>
      <Ontology_ID>GO:0034130</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A form of programmed cell death that begins when a cell receives internal or external signals that trigger the activity of proteolytic caspases, proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing (but maintenance of its integrity until the final stages of the process), and ends with the death of the cell.</Detail>
      <Keyword>Apoptosis</Keyword>
      <Ontology_ID>GO:0006915</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ionizing radiation stimulus. Ionizing radiation is radiation with sufficient energy to remove electrons from atoms and may arise from spontaneous decay of unstable isotopes, resulting in alpha and beta particles and gamma rays. Ionizing radiation also includes X-rays.</Detail>
      <Keyword>Cellular response to ionizing radiation</Keyword>
      <Ontology_ID>GO:0071479</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 4.</Detail>
      <Keyword>Toll-like receptor 4 signaling pathway</Keyword>
      <Ontology_ID>GO:0034142</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>An mRNA stabilization process in which one or more RNA-binding proteins associate with the 3'-untranslated region (UTR) of an mRNA.</Detail>
      <Keyword>3'-UTR-mediated mRNA stabilization</Keyword>
      <Ontology_ID>GO:0070935</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis, usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).</Detail>
      <Keyword>Response to stress</Keyword>
      <Ontology_ID>GO:0006950</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed, self-propelled movement of a cellular component without the involvement of an external agent such as a transporter or a pore.</Detail>
      <Keyword>Cellular component movement</Keyword>
      <Ontology_ID>GO:0006928</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription.</Detail>
      <Keyword>Regulation of transcription factor activity</Keyword>
      <Ontology_ID>GO:0051090</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 3.</Detail>
      <Keyword>Toll-like receptor 3 signaling pathway</Keyword>
      <Ontology_ID>GO:0034138</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cascade of processes induced by the detection of DNA damage within a cell.</Detail>
      <Keyword>Signal transduction in response to DNA damage</Keyword>
      <Ontology_ID>GO:0042770</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of a motile cell or organism, or the directed growth of a cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).</Detail>
      <Keyword>Chemotaxis</Keyword>
      <Ontology_ID>GO:0006935</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cellular senescence process associated with the dismantling of a cell as a response to environmental factors such as hydrogen peroxide or X-rays.</Detail>
      <Keyword>Stress-induced premature senescence</Keyword>
      <Ontology_ID>GO:0090400</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth factor stimulus.</Detail>
      <Keyword>Cellular response to growth factor stimulus</Keyword>
      <Ontology_ID>GO:0071363</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to a toll-like receptor where the MyD88 adaptor molecule mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response.</Detail>
      <Keyword>MyD88-dependent toll-like receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0002755</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals in which a stress-activated MAP kinase cascade relays one or more of the signals; MAP kinase cascades involve at least three protein kinase activities and culminate in the phosphorylation and activation of a MAP kinase.</Detail>
      <Keyword>Stress-activated MAPK cascade</Keyword>
      <Ontology_ID>GO:0051403</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation of peptidyl-serine to form peptidyl-O-phospho-L-serine.</Detail>
      <Keyword>Peptidyl-serine phosphorylation</Keyword>
      <Ontology_ID>GO:0018105</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals within the cell that are mediated by a member of the Ras superfamily of proteins switching to a GTP-bound active state.</Detail>
      <Keyword>Ras protein signal transduction</Keyword>
      <Ontology_ID>GO:0007265</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a relatively unspecialized cell acquires specialized features of a muscle cell.</Detail>
      <Keyword>Muscle cell differentiation</Keyword>
      <Ontology_ID>GO:0042692</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a relatively unspecialized monocyte acquires the specialized features of an osteoclast. An osteoclast is a specialized phagocytic cell associated with the absorption and removal of the mineralized matrix of bone tissue.</Detail>
      <Keyword>Osteoclast differentiation</Keyword>
      <Ontology_ID>GO:0030316</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of RNA on a template of DNA.</Detail>
      <Keyword>Transcription, DNA-dependent</Keyword>
      <Ontology_ID>GO:0006351</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of reactive oxygen species metabolic process.</Detail>
      <Keyword>Positive regulation of reactive oxygen species metabolic process</Keyword>
      <Ontology_ID>GO:2000379</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving mRNA, messenger RNA, which is responsible for carrying the coded genetic 'message', transcribed from DNA, to sites of protein assembly at the ribosomes.</Detail>
      <Keyword>MRNA metabolic process</Keyword>
      <Ontology_ID>GO:0016071</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.</Detail>
      <Keyword>Innate immune response</Keyword>
      <Ontology_ID>GO:0045087</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the nerve growth factor receptor binding to one of its physiological ligands.</Detail>
      <Keyword>Nerve growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0048011</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals generated as a consequence of binding to toll-like receptor 2.</Detail>
      <Keyword>Toll-like receptor 2 signaling pathway</Keyword>
      <Ontology_ID>GO:0034134</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>180</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>53</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>152</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>263</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>182</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>2</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>16</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>323</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES</Protein_Seq>
    <DNA_Seq>GGAACCGCGACCACTGGAGCCTTAGCGGGCGCAGCAGCTGGAACGGGAGTACTGCGACGCAGCCCGGAGTCGGCCTTGTAGGGGCGAAGGTGCAGGGAGATCGCGGCGGGCGCAGTCTTGAGCGCCGGAGCGCGTCCCTGCCCTTAGCGGGGCTTGCCCCAGTCGCAGGGGCACATCCAGCCGCTGCGGCTGACAGCAGCCGCGCGCGCGGGAGTCTGCGGGGTCGCGGCAGCCGCACCTGCGCGGGCGACCAGCGCAAGGTCCCCGCCCGGCTGGGCGGGCAGCAAGGGCCGGGGAGAGGGTGCGGGTGCAGGCGGGGGCCCCACAGGGCCACCTTCTTGCCCGGCGGCTGCCGCTGGAAAATGTCTCAGGAGAGGCCCACGTTCTACCGGCAGGAGCTGAACAAGACAATCTGGGAGGTGCCCGAGCGTTACCAGAACCTGTCTCCAGTGGGCTCTGGCGCCTATGGCTCTGTGTGTGCTGCTTTTGACACAAAAACGGGGTTACGTGTGGCAGTGAAGAAGCTCTCCAGACCATTTCAGTCCATCATTCATGCGAAAAGAACCTACAGAGAACTGCGGTTACTTAAACATATGAAACATGAAAATGTGATTGGTCTGTTGGACGTTTTTACACCTGCAAGGTCTCTGGAGGAATTCAATGATGTGTATCTGGTGACCCATCTCATGGGGGCAGATCTGAACAACATTGTGAAATGTCAGAAGCTTACAGATGACCATGTTCAGTTCCTTATCTACCAAATTCTCCGAGGTCTAAAGTATATACATTCAGCTGACATAATTCACAGGGACCTAAAACCTAGTAATCTAGCTGTGAATGAAGACTGTGAGCTGAAGATTCTGGATTTTGGACTGGCTCGGCACACAGATGATGAAATGACAGGCTACGTGGCCACTAGGTGGTACAGGGCTCCTGAGATCATGCTGAACTGGATGCATTACAACCAGACAGTTGATATTTGGTCAGTGGGATGCATAATGGCCGAGCTGTTGACTGGAAGAACATTGTTTCCTGGTACAGACCATATTAACCAGCTTCAGCAGATTATGCGTCTGACAGGAACACCCCCCGCTTATCTCATTAACAGGATGCCAAGCCATGAGGCAAGAAACTATATTCAGTCTTTGACTCAGATGCCGAAGATGAACTTTGCGAATGTATTTATTGGTGCCAATCCCCTGGCTGTCGACTTGCTGGAGAAGATGCTTGTATTGGACTCAGATAAGAGAATTACAGCGGCCCAAGCCCTTGCACATGCCTACTTTGCTCAGTACCACGATCCTGATGATGAACCAGTGGCCGATCCTTATGATCAGTCCTTTGAAAGCAGGGACCTCCTTATAGATGAGTGGAAAAGCCTGACCTATGATGAAGTCATCAGCTTTGTGCCACCACCCCTTGACCAAGAAGAGATGGAGTCCTGAGCACCTGGTTTCTGTTCTGTTGATCCCACTTCACTGTGAGGGGAAGGCCTTTTCACGGGAACTCTCCAAATATTATTCAAGTGCCTCTTGTTGCAGAGATTTCCTCCATGGTGGAAGGGGGTGTGCGTGCGTGTGCGTGCGTGTTAGTGTGTGTGCATGTGTGTGTCTGTCTTTGTGGGAGGGTAAGACAATATGAACAAACTATGATCACAGTGACTTTACAGGAGGTTGTGGATGCTCCAGGGCAGCCTCCACCTTGCTCTTCTTTCTGAGAGTTGGCTCAGGCAGACAAGAGCTGCTGTCCTTTTAGGAATATGTTCAATGCAAAGTAAAAAAATATGAATTGTCCCCAATCCCGGTCATGCTTTTGCCACTTTGGCTTCTCCTGTGACCCCACCTTGACGGTGGGGCGTAGACTTGACAACATCCCACAGTGGCACGGAGAGAAGGCCCATACCTTCTGGTTGCTTCAGACCTGACACCGTCCCTCAGTGATACGTACAGCCAAAAAGGACCAACTGGCTTCTGTGCACTAGCCTGTGATTAACTTGCTTAGTATGGTTCTCAGATCTTGACAGTATATTTGAAACTGTAAATATGTTTGTGCCTTAAAAGGAGAGAAGAAAGTGTAGATAGTTAAAAGACTGCAGCTGCTGAAGTTCTGAGCCGGGCAAGTCGAGAGGGCTGTTGGACAGCTGCTTGTGGGCCCGGAGTAATCAGGCAGCCTTCATAGGCGGTCATGTGTGCATGTGAGCACATGCGTATATGTGCGTCTCTCTTTCTCCCTCACCCCCAGGTGTTGCCATTTCTCTGCTTACCCTTCACCTTTGGTGCAGAGGTTTCTTGAATATCTGCCCCAGTAGTCAGAAGCAGGTTCTTGATGTCATGTACTTCCTGTGTACTCTTTATTTCTAGCAGAGTGAGGATGTGTTTTGCACGTCTTGCTATTTGAGCATGCACAGCTGCTTGTCCTGCTCTCTTCAGGAGGCCCTGGTGTCAGGCAGGTTTGCCAGTGAAGACTTCTTGGGTAGTTTAGATCCCATGTCACCTCAGCTGATATTATGGCAAGTGATATCACCTCTCTTCAGCCCCTAGTGCTATTCTGTGTTGAACACAATTGATACTTCAGGTGCTTTTGATGTGAAAATCATGAAAAGAGGAACAGGTGGATGTATAGCATTTTTATTCATGCCATCTGTTTTCAACCAACTATTTTTGAGGAATTATCATGGGAAAAGACCAGGGCTTTTCCCAGGAATATCCCAAACTTCGGAAACAAGTTATTCTCTTCACTCCCAATAACTAATGCTAAGAAATGCTGAAAATCAAAGTAAAAAATTAAAGCCCATAAGGCCAGAAACTCCTTTTGCTGTCTTTCTCTAAATATGATTACTTTAAAATAAAAAAGTAACAAGGTGTCTTTTCCACTCCTATGGAAAAGGGTCTTCTTGGCAGCTTAACATTGACTTCTTGGTTTGGGGAGAAATAAATTTTGTTTCAGAATTTTGTATATTGTAGGAATCCCTTTGAGAATGTGATTCCTTTTGATGGGGAGAAAGGGCAAATTATTTTAATATTTTGTATTTTCAACTTTATAAAGATAAAATATCCTCAGGGGTGGAGAAGTGTCGTTTTCATAACTTGCTGAATTTCAGGCATTTTGTTCTACATGAGGACTCATATATTTAAGCCTTTTGTGTAATAAGAAAGTATAAAGTCACTTCCAGTGTTGGCTGTGTGACAGAATCTTGTATTTGGGCCAAGGTGTTTCCATTTCTCAATCAGTGCAGTGATACATGTACTCCAGAGGGACAGGGTGGACCCCCTGAGTCAACTGGAGCAAGAAGGAAGGAGGCAGACTGATGGCGATTCCCTCTCACCCGGGACTCTCCCCCTTTCAAGGAAAGTGAACCTTTAAAGTAAAGGCCTCATCTCCTTTATTGCAGTTCAAATCCTCACCATCCACAGCAAGATGAATTTTATCAGCCATGTTTGGTTGTAAATGCTCGTGTGATTTCCTACAGAAATACTGCTCTGAATATTTTGTAATAAAGGTCTTTGCACATGTGACCACATACGTGTTAGGAGGCTGCATGCTCTGGAAGCCTGGACTCTAAGCTGGAGCTCTTGGAAGAGCTCTTCGGTTTCTGAGCATAATGCTCCCATCTCCTGATTTCTCTGAACAGAAAACAAAAGAGAGAATGAGGGAAATTGCTATTTTATTTGTATTCATGAACTTGGCTGTAATCAGTTATGCCGTATAGGATGTCAGACAATACCACTGGTTAAAATAAAGCCTATTTTTCAAATTT</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Pancreas</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Lung</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Heart</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Placenta</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Skeletal muscle</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Brain</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>MAPK14</Gene_Name>
    <Gene_Alias>CSBP; CSBP1; CSBP2; CSPB1; MXI2; SAPK2A</Gene_Alias>
    <Gene_ID>1432</Gene_ID>
    <Genbank_ACCN>NM_001315</Genbank_ACCN>
    <Protein_ACCN>NP_001306</Protein_ACCN>
    <HGNC_ID>6876</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/1432</Gene_URL>
    <UCSC_ID>uc003olr.3</UCSC_ID>
    <EMBL_ID>ENSG00000112062</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q07352</Uniprot_ID>
      <Gene_Name>ZFP36L1</Gene_Name>
      <EBI_ID>EBI-721823</EBI_ID>
      <PPI_EBI_URL>EBI-73946,EBI-721823</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q92574</Uniprot_ID>
      <Gene_Name>TSC1</Gene_Name>
      <EBI_ID>EBI-1047085</EBI_ID>
      <PPI_EBI_URL>EBI-73946,EBI-1047085</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P06400</Uniprot_ID>
      <Gene_Name>RB1</Gene_Name>
      <EBI_ID>EBI-491274</EBI_ID>
      <PPI_EBI_URL>EBI-73946,EBI-491274</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P49137</Uniprot_ID>
      <Gene_Name>MAPKAPK2</Gene_Name>
      <EBI_ID>EBI-993299</EBI_ID>
      <PPI_EBI_URL>EBI-73946,EBI-993299</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O75676</Uniprot_ID>
      <Gene_Name>RPS6KA4</Gene_Name>
      <EBI_ID>EBI-73933</EBI_ID>
      <PPI_EBI_URL>EBI-73946,EBI-73933</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8NEM7</Uniprot_ID>
      <Gene_Name>FAM48A</Gene_Name>
      <EBI_ID>EBI-946984</EBI_ID>
      <PPI_EBI_URL>EBI-73946,EBI-946984</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Alexander Disease</Disease_Name>
      <Disease_Detail>Alexander Disease</Disease_Detail>
      <Disease_DB>ALX003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/alexander_disease?search=MAPK14#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Influenza</Disease_Name>
      <Disease_Detail>Influenza</Disease_Detail>
      <Disease_DB>INF038</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/influenza?search=MAPK14#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of a N-Phenyl-N'-Naphthylurea analog in complex with p38 MAP kinase</PDB_Title>
      <PDB_ID>3GI3</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GI3</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490123</ASD_Ligand>
      <Ligand_Name>N-{5-tert-butyl-2-methoxy-3-[({4-[6-(morpholin- 4-ylmethyl)pyridin-3
-yl]naphthalen-1-yl}carbamoyl)amino]phenyl}methanesulfonamide</Ligand_Name>
      <PubMed_Title>Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.</PubMed_Title>
      <Author>Cirillo PF, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2009 May 1;19(9):2386-91. Epub  2009 Mar 26.</Journal>
      <PubMed_ID>19356929</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>mitogen activated protein kinase p38alpha (D176A) activating mutant</PDB_Title>
      <PDB_ID>2FSO</PDB_ID>
      <Resolution>1.83</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FSO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Structures of p38alpha Active Mutants Reveal Conformational Changes in L16 Loop that Induce Autophosphorylation and Activation</PubMed_Title>
      <Author>Diskin R, et al.</Author>
      <Journal>J Mol Biol.2007 Jan 5;365(1):66-76. Epub  2006 Aug 22.</Journal>
      <PubMed_ID>17059827</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF APO, UNPHOSPHORYLATED, P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN</PDB_Title>
      <PDB_ID>1WFC</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WFC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of p38 mitogen-activated protein kinase.</PubMed_Title>
      <Author>Wilson KP, et al.</Author>
      <Journal>J Biol Chem.1996 Nov 1;271(44):27696-700.</Journal>
      <PubMed_ID>8910361</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 Complexed with a quinazoline inhibitor</PDB_Title>
      <PDB_ID>3DT1</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DT1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-cyclopropyl-4-methyl-3-{2-[(2-morpholin- 4-ylethyl)amino]quinazolin-6
-yl}benzamide</Ligand_Name>
      <PubMed_Title>Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.</PubMed_Title>
      <Author>Herberich B, et al.</Author>
      <Journal>J Med Chem.2008 Oct 23;51(20):6271-9. Epub  2008 Sep 26.</Journal>
      <PubMed_ID>18817365</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>mitogen activated protein kinase p38alpha (D176A+F327L) activating mutant</PDB_Title>
      <PDB_ID>2FST</PDB_ID>
      <Resolution>1.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FST</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Structures of p38alpha Active Mutants Reveal Conformational Changes in L16 Loop that Induce Autophosphorylation and Activation</PubMed_Title>
      <Author>Diskin R, et al.</Author>
      <Journal>J Mol Biol.2007 Jan 5;365(1):66-76. Epub  2006 Aug 22.</Journal>
      <PubMed_ID>17059827</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025</PDB_Title>
      <PDB_ID>1BL7</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BL7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2- AMINO-4-PYRIMIDINYL)-IMIDAZOLE</Ligand_Name>
      <PubMed_Title>Structural basis of inhibitor selectivity in MAP kinases.</PubMed_Title>
      <Author>Wang Z, et al.</Author>
      <Journal>Structure.1998 Sep 15;6(9):1117-28.</Journal>
      <PubMed_ID>9753691</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with Scios-469</PDB_Title>
      <PDB_ID>3HUB</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HUB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ 2-(6-chloro-5-{[(2R,5S)-4-(4-fluorobenzyl)- 2,5-dimethylpiperazin-1-yl]carbonyl}
-1-methyl- 1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide</Ligand_Name>
      <PubMed_Title>Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2010 Mar 31;132(12):4152-60.</Journal>
      <PubMed_ID>20201574</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>mitogen activated protein kinase p38alpha (D176A+F327S) activating mutant form-A</PDB_Title>
      <PDB_ID>2FSL</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FSL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Structures of p38alpha Active Mutants Reveal Conformational Changes in L16 Loop that Induce Autophosphorylation and Activation</PubMed_Title>
      <Author>Diskin R, et al.</Author>
      <Journal>J Mol Biol.2007 Jan 5;365(1):66-76. Epub  2006 Aug 22.</Journal>
      <PubMed_ID>17059827</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with RL38</PDB_Title>
      <PDB_ID>3HV7</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HV7</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740003</ASD_Ligand>
      <Ligand_Name>1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol- 5-yl]-3-naphthalen-1-ylurea $ B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Displacement assay for the detection of stabilizers of inactive kinase conformations.</PubMed_Title>
      <Author>Kluter, S., et al.</Author>
      <Journal>J Med Chem. 2010 Jan 14;53(1):357-67.</Journal>
      <PubMed_ID>19928858</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN P38 MAP KINASE INHIBITOR COMPLEX</PDB_Title>
      <PDB_ID>1IAN</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IAN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL- PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE</Ligand_Name>
      <PubMed_Title>A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket.</PubMed_Title>
      <Author>Tong L, et al.</Author>
      <Journal>Nat Struct Biol.1997 Apr;4(4):311-6.</Journal>
      <PubMed_ID>9095200</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with RL113</PDB_Title>
      <PDB_ID>3LFD</PDB_ID>
      <Resolution>3.4</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LFD</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03492008</ASD_Ligand>
      <PubMed_Title>Development of novel thiazole-urea compounds which stabalize the inactive conformation of p38 alpha</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Mutagenesis of p38 MAP Kinase eshtablishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state</PDB_Title>
      <PDB_ID>2PKJ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PKJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ZINC ION</Ligand_Name>
      <PubMed_Title>3MH0: Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.</PubMed_Title>
      <Author>Chen, Y, et.al.</Author>
      <Journal>Nat Struct Mol Biol. 2007 Jun;14(6):527-34. Epub 2007 May 27.</Journal>
      <PubMed_ID>17529992</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with a Benzylpiperazin-Pyrrol</PDB_Title>
      <PDB_ID>3IW6</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IW6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ ethyl 4-[(4-benzylpiperazin-1-yl)carbonyl]- 1-ethyl-3,5-dimethyl-1H-pyrrole-2
-carboxylate</Ligand_Name>
      <PubMed_Title>High-Throughput Screening To Identify Inhibitors Which Stabilize Inactive Kinase Conformations in p38alpha</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2009 Dec 30;131(51):18478-88.</Journal>
      <PubMed_ID>19950957</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A Novel Lipid Binding Site in the p38 alpha MAP Kinase</PDB_Title>
      <PDB_ID>2NPQ</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2NPQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>A novel lipid binding site formed by the MAP kinase insert in p38 alpha.</PubMed_Title>
      <Author>Diskin R, et al.</Author>
      <Journal>J Mol Biol.2008 Jan 4;375(1):70-9. Epub  2007 Sep 8.</Journal>
      <PubMed_ID>17999933</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of p38 alpha in complex with a pyridinylimidazole inhibitor</PDB_Title>
      <PDB_ID>1OUK</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OUK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-[5-[2-(1-PHENYL-ETHYLAMINO)-PYRIMIDIN-4- YL]-1-METHYL-4-(3
-TRIFLUOROMETHYLPHENYL)- 1H-IMIDAZOL-2-YL]-PIPERIDINE $ SULFATE ION</Ligand_Name>
      <PubMed_Title>Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity</PubMed_Title>
      <Author>Fitzgerald CE, et al.</Author>
      <Journal>Nat Struct Biol.2003 Sep;10(9):764-9. Epub  2003 Aug 3.</Journal>
      <PubMed_ID>12897767</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Conformational plasticity of p38 MAP kinase DFG-motif mutants in response to inhibitor binding</PDB_Title>
      <PDB_ID>3O8T</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3O8T</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740008</ASD_Ligand>
      <PubMed_Title>Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR</PDB_Title>
      <PDB_ID>1W84</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W84</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-(2-PYRIDIN-4-YLETHYL)-1H-INDOLE</Ligand_Name>
      <PubMed_Title>Identification of Novel P38Alpha Map Kinase Inhibitors Using Fragment-Based Lead Generation</PubMed_Title>
      <Author>Gill AL, et al.</Author>
      <Journal>J Med Chem.2005 Jan 27;48(2):414-26.</Journal>
      <PubMed_ID>15658855</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Morpholino pyrrolotriazine P38 Alpha Map Kinase inhibitor compound 2</PDB_Title>
      <PDB_ID>3BV3</PDB_ID>
      <Resolution>2.59</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BV3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-methyl-4-[(2-methyl-5-{[(3-morpholin-4- ylphenyl)carbonyl]amino}phenyl)amino]
-N-[(1S)- 1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine- 6-carboxamide</Ligand_Name>
      <PubMed_Title>Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.</PubMed_Title>
      <Author>Wrobleski ST, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Apr 15;18(8):2739-44. Epub  2008 Mar 4.</Journal>
      <PubMed_ID>18364256</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridinone Inhibitor</PDB_Title>
      <PDB_ID>3GFE</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GFE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-cyclopropyl-3-{[1-(2,4-difluorophenyl)- 7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo
[3,4- b]pyridin-4-yl]amino}-4-methylbenzamide</Ligand_Name>
      <PubMed_Title>Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.</PubMed_Title>
      <Author>Wurz RP, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2009 Aug 15;19(16):4724-8. Epub  2009 Jun 17.</Journal>
      <PubMed_ID>19574047</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 alpha map kinase complexed with BMS-640994</PDB_Title>
      <PDB_ID>3BX5</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BX5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-[2-methyl-5-(methylcarbamoyl)phenyl]-2- {[(1R)-1-methylpropyl]amino}-1,3
-thiazole- 5-carboxamide</Ligand_Name>
      <PubMed_Title>The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor</PubMed_Title>
      <Author>Hynes J Jr, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Mar 15;18(6):1762-7. Epub  2008 Feb 16.</Journal>
      <PubMed_ID>18313298</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of p38alpha in complex with an arylpyridazinone</PDB_Title>
      <PDB_ID>2I0H</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2I0H</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-(3-{(2-CHLORO-4-FLUOROPHENYL)[1-(2-CHLOROPHENYL)- 6-OXO-1,6-DIHYDROPYRIDAZIN-3
-YL]AMINO}PROPYL)- 1H-ISOINDOLE-1,3(2H)-DIONE $ GLYCEROL</Ligand_Name>
      <PubMed_Title>p38 MAP Kinase Inhibitors Part 6: 2-Arylpyridazin-3-ones as templates for inhibitor design.</PubMed_Title>
      <Author>Natarajan SR, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2006 Nov 15;16(22):5809-13. Epub  2006 Aug 30.</Journal>
      <PubMed_ID>16945533</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-8-methyl-2-((R)-1-methyl-2-tetrazol-2-yl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one</PDB_Title>
      <PDB_ID>3FMH</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FMH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-8-methyl-2-{[(1R)- 1-methyl-2-(2H-tetrazol-2
-yl)ethyl]amino}pyrido[2,3- d]pyrimidin-7(8H)-one</Ligand_Name>
      <PubMed_Title>The Discovery of Pamapimod and R1487 as Orally Bioavailable and Highly Selective Inhibitors of p38 Map Kinase</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of human p38alpha with N-[4-methyl-3-(6-{[2-(1-methylpyrrolidin-2-yl)ethyl]amino}pyridine-3-amido)phenyl]-2-(morpholin-4-yl)pyridine-4-carboxamide</PDB_Title>
      <PDB_ID>3KQ7</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KQ7</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490118</ASD_Ligand>
      <Ligand_Name>ACETATE ION $ N-(2-methyl-5-{[(2-morpholin-4-ylpyridin- 4-yl)carbonyl]amino}phenyl)-6-({2-[
(2S)-1- methylpyrrolidin-2-yl]ethyl}amino)pyridine- 3-carboxamide</Ligand_Name>
      <PubMed_Title>Structure of human p38alpha with N-[4-methyl-3-(6-{[2-(1-methylpyrrolidin-2-yl)ethyl]amino}pyridine-3-amido)phenyl]-2-(morpholin-4-yl)pyridine-4-carboxamide</PubMed_Title>
      <Author>Cheng, R.K.Y., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with RO4499</PDB_Title>
      <PDB_ID>3FI4</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FI4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(2S)-1-{[3-(2-chlorophenyl)-6-(2,4-difluorophenoxy)- 1H-pyrazolo[3,4-d]pyrimidin
-4-yl]amino}propan- 2-ol</Ligand_Name>
      <PubMed_Title>Mapping Binding Pocket Volume: Potential Applications towards Ligand Design and Selectivity</PubMed_Title>
      <Author>Arora, N., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995</PDB_Title>
      <PDB_ID>1BL6</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BL6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL- 5-(4-PYRIDYL)-IMIDAZOLE</Ligand_Name>
      <PubMed_Title>Structural basis of inhibitor selectivity in MAP kinases.</PubMed_Title>
      <Author>Wang Z, et al.</Author>
      <Journal>Structure.1998 Sep 15;6(9):1117-28.</Journal>
      <PubMed_ID>9753691</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Conformational plasticity of p38 MAP kinase DFG mutants in response to inhibitor binding</PDB_Title>
      <PDB_ID>3OBJ</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OBJ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740008</ASD_Ligand>
      <PubMed_Title>Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with RO5634</PDB_Title>
      <PDB_ID>3FL4</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FL4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-3-(2-methylphenyl)- 1H-pyrazolo[3,4-d]pyrimidine</Ligand_Name>
      <PubMed_Title>Mapping Binding Pocket Volume: Potential Applications towards Ligand Design and Selectivity</PubMed_Title>
      <Author>Arora, N., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE STRUCTURE OF P38ALPHA</PDB_Title>
      <PDB_ID>1R39</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1R39</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>SULFATE ION</Ligand_Name>
      <PubMed_Title>Lattice stabilization and enhanced diffraction in human p38 alpha crystals by protein engineering.</PubMed_Title>
      <Author>Patel SB, et al.</Author>
      <Journal>Biochim Biophys Acta.2004 Jan 14;1696(1):67-73.</Journal>
      <PubMed_ID>14726206</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR</PDB_Title>
      <PDB_ID>1OZ1</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OZ1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-(4-FLUOROPHENYL)-2-PYRIDIN-4-YL-1H-PYRROLO[3,2- B]PYRIDIN-1-OL</Ligand_Name>
      <PubMed_Title>Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.</PubMed_Title>
      <Author>Trejo A, et al.</Author>
      <Journal>J Med Chem.2003 Oct 23;46(22):4702-13.</Journal>
      <PubMed_ID>14561090</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with RL24</PDB_Title>
      <PDB_ID>3HV5</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HV5</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490114</ASD_Ligand>
      <Ligand_Name>2-(N-MORPHOLINO)-ETHANESULFONIC ACID $ B-OCTYLGLUCOSIDE $ 1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol- 5-yl]-3-{3-[(6-nitroquinolin-4
-yl)amino]phenyl}urea</Ligand_Name>
      <PubMed_Title>Displacement assay for the detection of stabilizers of inactive kinase conformations.</PubMed_Title>
      <Author>Kluter, S., et al.</Author>
      <Journal>J Med Chem. 2010 Jan 14;53(1):357-67.</Journal>
      <PubMed_ID>19928858</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE COMPLEX STRUCTURE OF THE MAP KINASE P38/Compound 14b</PDB_Title>
      <PDB_ID>3HA8</PDB_ID>
      <Resolution>2.48</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HA8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N~2~-{4-[6-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)- 1H-benzimidazol-1-yl]-6
-ethoxy-1,3,5-triazin- 2-yl}-3-(2,2-dimethyl-4H-1,3-benzodioxin- 6-yl)-N-methyl-L
-alaninamide</Ligand_Name>
      <PubMed_Title>Design, Synthesis, and Selection of DNA Encoded Small Molecule Libraries</PubMed_Title>
      <Author>Clark, M.A., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with BIRB 796</PDB_Title>
      <PDB_ID>1KV2</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KV2</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740009</ASD_Ligand>
      <Ligand_Name>1-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)- 3-[4-(2-MORPHOLIN-4-YL-ETHOXY)
-NAPHTHALEN- 1-YL]-UREA</Ligand_Name>
      <PubMed_Title>Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.</PubMed_Title>
      <Author>Pargellis C, et al.</Author>
      <Journal>Nat Struct Biol.2002 Apr;9(4):268-72.</Journal>
      <PubMed_ID>11896401</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with RO7125</PDB_Title>
      <PDB_ID>3FKN</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FKN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-[2-chloro-5-(methylsulfonyl)phenyl]-6-(2,4- difluorophenoxy)-1H-pyrazolo[3,4
-d]pyrimidine</Ligand_Name>
      <PubMed_Title>Mapping Binding Pocket Volume: Potential Applications towards Ligand Design and Selectivity</PubMed_Title>
      <Author>Arora, N., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human p38alpha MAP kinase</PDB_Title>
      <PDB_ID>3HVC</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HVC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE</Ligand_Name>
      <PubMed_Title>p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses.</PubMed_Title>
      <Author>Perry JJ, et al.</Author>
      <Journal>J Mol Biol.2009 Aug 7;391(1):1-11. Epub  2009 Jun 6.</Journal>
      <PubMed_ID>19501598</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of P38 in complex with 4-anilino quinoline inhibitor</PDB_Title>
      <PDB_ID>2ZAZ</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZAZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>ACETATE ION $ GLYCEROL $ 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin- 7-yl}-1,3-thiazole-2
-carbaldehyde</Ligand_Name>
      <PubMed_Title>Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode</PubMed_Title>
      <Author>Angell RM, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Jan 1;18(1):318-23. Epub  2007 Nov 19.</Journal>
      <PubMed_ID>18006306</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with RL98</PDB_Title>
      <PDB_ID>3LFB</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LFB</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03492005</ASD_Ligand>
      <PubMed_Title>Development of novel thiazole-urea compounds which stabalize the inactive conformation of p38 alpha</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of p38 Alpha in Complex with a Selective Pyridazine Inhibitor</PDB_Title>
      <PDB_ID>1YQJ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YQJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6((S)-3-BENZYLPIPERAZIN-1-YL)-3-(NAPHTHALEN- 2-YL)-4-(PYRIDIN-4-YL)PYRAZINE $ SULFATE ION</Ligand_Name>
      <PubMed_Title>Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.</PubMed_Title>
      <Author>Tamayo N, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2005 May 2;15(9):2409-13.</Journal>
      <PubMed_ID>15837335</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)-2-isopropylamino-8-methyl-8h-pyrido[2,3-d]pyrimidin-7-one</PDB_Title>
      <PDB_ID>3FLY</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FLY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-8-methyl-2-[(1-methylethyl)amino]pyrido[2,3- d]pyrimidin
-7(8H)-one</Ligand_Name>
      <PubMed_Title>The Discovery of Pamapimod, R1503 and R1487 as Orally Bioavailable and Highly Selective Inhibitors of p38 Map Kinase</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with RO3668</PDB_Title>
      <PDB_ID>3FKO</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FKO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-(2-chlorophenyl)-6-(2-fluorophenoxy)-2H- indazole</Ligand_Name>
      <PubMed_Title>Mapping Binding Pocket Volume: Potential Applications towards Ligand Design and Selectivity</PubMed_Title>
      <Author>Arora, N., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human p38alpha complexed with SD-0006</PDB_Title>
      <PDB_ID>3HL7</PDB_ID>
      <Resolution>1.88</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HL7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol- 3-yl]pyridine $ 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl- 1H-pyrazol-3-yl]piperidin-1-yl}-2
-oxoethanol</Ligand_Name>
      <PubMed_Title>Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.</PubMed_Title>
      <Author>Xing L, et al.</Author>
      <Journal>Biochemistry.2009 Jul 14;48(27):6402-11.</Journal>
      <PubMed_ID>19496616</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP kinase in complex with NP-F11 and RL87</PDB_Title>
      <PDB_ID>4EH9</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4EH9</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490133;ASD03490134</ASD_Ligand>
      <PubMed_Title>Natural-product-derived fragments for fragment-based ligand discovery.</PubMed_Title>
      <Author>Over, B., et al.</Author>
      <Journal>Nat Chem(2012)5:21-28</Journal>
      <PubMed_ID>23247173</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human P38 MAP Kinase in Complex with Inhibitor 1a</PDB_Title>
      <PDB_ID>1ZYJ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZYJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE $ B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes.</PubMed_Title>
      <Author>Michelotti EL, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2005 Dec 1;15(23):5274-9. Epub  2005 Sep 19.</Journal>
      <PubMed_ID>16169718</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of p38 kinase bound to pyrimido-pyridazinone inhibitor</PDB_Title>
      <PDB_ID>3FC1</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FC1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]- 6H-pyrimido[1,6
-b]pyridazin-6-one $ CHLORIDE ION</Ligand_Name>
      <PubMed_Title>Evaluating the molecular mechanics poisson-boltzmann surface area free energy method using a congeneric series of ligands to p38 MAP kinase.</PubMed_Title>
      <Author>Pearlman DA, et al.</Author>
      <Journal>J Med Chem.2005 Dec 1;48(24):7796-807.</Journal>
      <PubMed_ID>16302819</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.</PDB_Title>
      <PDB_ID>1WBT</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WBT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490102</ASD_Ligand>
      <Ligand_Name>3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN- 4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE</Ligand_Name>
      <PubMed_Title>Identification of Novel P38Alpha Map Kinase Inhibitors Using Fragment-Based Lead Generation.</PubMed_Title>
      <Author>Gill AL, et al.</Author>
      <Journal>J Med Chem.2005 Jan 27;48(2):414-26.</Journal>
      <PubMed_ID>15658855</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FRAGMENT BASED P38 INHIBITORS</PDB_Title>
      <PDB_ID>1WBN</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WBN</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490094</ASD_Ligand>
      <Ligand_Name>N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO- 3-[(PYRIDIN-3
-YLOXY)METHYL]PHENYL}UREA</Ligand_Name>
      <PubMed_Title>Identification of Novel P38Alpha Map Kinase Inhibitors Using Fragment-Based Lead Generation.</PubMed_Title>
      <Author>Gill AL, et al.</Author>
      <Journal>J Med Chem.2005 Jan 27;48(2):414-26.</Journal>
      <PubMed_ID>15658855</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>p38-alpha complexed with Compound 10</PDB_Title>
      <PDB_ID>3NEW</PDB_ID>
      <Resolution>2.51</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NEW</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03498001</ASD_Ligand>
      <PubMed_Title>Discovery and Characterization of Non-ATP Site Inhibitors of the Mitogen Activated Protein (MAP) Kinases.</PubMed_Title>
      <Author>Comess, K.M., et al.</Author>
      <Journal>Acs Chem.Biol.(2011)6:234-244</Journal>
      <PubMed_ID>21090814</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Two Classes of p38alpha MAP Kinase Inhibitors Having a Common Diphenylether Core but Exhibiting Divergent Binding Modes</PDB_Title>
      <PDB_ID>1ZZ2</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZZ2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-[3-(4-FLUOROPHENOXY)PHENYL]-4-[(2-HYDROXYBENZYL)AMINO]PIPERIDINE- 1
-SULFONAMIDE $ B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes.</PubMed_Title>
      <Author>Michelotti EL, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2005 Dec 1;15(23):5274-9. Epub  2005 Sep 19.</Journal>
      <PubMed_ID>16169718</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Morpholino pyrrolotriazine P38 Alpha map kinase inhibitor compound 30</PDB_Title>
      <PDB_ID>3BV2</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BV2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-methyl-4-[(2-methyl-5-{[(2-morpholin-4- ylpyridin-4
-yl)carbonyl]amino}phenyl)amino]- N-(1-phenylethenyl)pyrrolo[2,1-f][1,2,4]triazine- 6-carboxamide</Ligand_Name>
      <PubMed_Title>Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.</PubMed_Title>
      <Author>Wrobleski ST, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Apr 15;18(8):2739-44. Epub  2008 Mar 4.</Journal>
      <PubMed_ID>18364256</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>p38a-perifosine Complex</PDB_Title>
      <PDB_ID>4E6C</PDB_ID>
      <Resolution>2.39</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4E6C</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490131</ASD_Ligand>
      <PubMed_Title>Lipid Molecules Induce p38 alpha Activation via a Novel Molecular Switch.</PubMed_Title>
      <Author>Tzarum, N., et al.</Author>
      <Journal>J.Mol.Biol.(2012)424:339-353</Journal>
      <PubMed_ID>23079240</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of P38 Kinase in Complex with A Biaryl Amide Inhibitor</PDB_Title>
      <PDB_ID>3E92</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E92</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-cyclopropyl-2',6-dimethyl-4'-(5-methyl- 1,3,4-oxadiazol-2-yl)biphenyl-3
-carboxamide $ GLYCEROL</Ligand_Name>
      <PubMed_Title>Kinase array design, back to front: Biaryl amides</PubMed_Title>
      <Author>Baldwin I, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Oct 1;18(19):5285-9. Epub  2008 Aug 22.</Journal>
      <PubMed_ID>18789685</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>p38alpha bound to pyrazolourea</PDB_Title>
      <PDB_ID>2BAJ</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BAJ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490106</ASD_Ligand>
      <Ligand_Name>(S)-{[(3R)-5-TERT-BUTYL-2-PHENYL-2,3-DIHYDRO- 1H-PYRAZOL-3-YL]AMINO}[(2,3
-DICHLOROPHENYL)AMINO]METHANOL</Ligand_Name>
      <PubMed_Title>Prevention of MKK6-Dependent Activation by Binding to p38alpha MAP Kinase</PubMed_Title>
      <Author>Sullivan JE, et al.</Author>
      <Journal>Biochemistry.2005 Dec 20;44(50):16475-90.</Journal>
      <PubMed_ID>16342939</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38ALPHA MAP KINASE BOUND TO CMPD 2</PDB_Title>
      <PDB_ID>4AA0</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4AA0</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490109</ASD_Ligand>
      <PubMed_Title>The Discovery of N-Cyclopropyl-4-Methyl-3-[6--(4-Methylpiperazin-1-Yl-4-Oxoquinazolin-3(4H)-Yl]Benzamide (Azd6703), a Clinical P38Alpha Map Kinase Inhibitor for the Treatment of Inflammatory Diseases</PubMed_Title>
      <Author>Brown, D.S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:3879</Journal>
      <PubMed_ID>22608965</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.</PDB_Title>
      <PDB_ID>1WBV</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WBV</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490097</ASD_Ligand>
      <Ligand_Name>DIMETHYL SULFOXIDE $ GLYCEROL $ 3-FLUORO-N-1H-INDOL-5-YL-5-MORPHOLIN-4-YLBENZAMIDE</Ligand_Name>
      <PubMed_Title>Identification of Novel P38Alpha Map Kinase Inhibitors Using Fragment-Based Lead Generation.</PubMed_Title>
      <Author>Gill AL, et al.</Author>
      <Journal>J Med Chem.2005 Jan 27;48(2):414-26.</Journal>
      <PubMed_ID>15658855</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38ALPHA MAP KINASE BOUND TO CMPD 8</PDB_Title>
      <PDB_ID>4A9Y</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4A9Y</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490119</ASD_Ligand>
      <PubMed_Title>The Discovery of N-Cyclopropyl-4-Methyl-3-[6--(4-Methylpiperazin-1-Yl-4-Oxoquinazolin-3(4H)-Yl]Benzamide (Azd6703), a Clinical P38Alpha Map Kinase Inhibitor for the Treatment of Inflammatory Diseases</PubMed_Title>
      <Author>Brown, D.S., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:3879</Journal>
      <PubMed_ID>22608965</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with RL39</PDB_Title>
      <PDB_ID>3HV6</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HV6</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490122</ASD_Ligand>
      <Ligand_Name>1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol- 5-yl]-3-[4-(2-morpholin-4
-ylethoxy)phenyl]urea $ B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Displacement assay for the detection of stabilizers of inactive kinase conformations.</PubMed_Title>
      <Author>Kluter, S., et al.</Author>
      <Journal>J Med Chem. 2010 Jan 14;53(1):357-67.</Journal>
      <PubMed_ID>19928858</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655</PDB_Title>
      <PDB_ID>1BMK</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BMK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-(FLUOROPHENYL)-1-CYCLOPROPYLMETHYL-5-(2- AMINO-4-PYRIMIDINYL)IMIDAZOLE</Ligand_Name>
      <PubMed_Title>Structural basis of inhibitor selectivity in MAP kinases.</PubMed_Title>
      <Author>Wang Z, et al.</Author>
      <Journal>Structure.1998 Sep 15;6(9):1117-28.</Journal>
      <PubMed_ID>9753691</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of p38alpha in complex with a dihydroquinazolinone</PDB_Title>
      <PDB_ID>3GC7</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GC7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)- 7-[1-(1
-methylethyl)piperidin-4-yl]-3,4-dihydroquinazolin- 2(1H)-one</Ligand_Name>
      <PubMed_Title>The three-dimensional structure of MAP kinase p38[beta]: different features of the ATP-binding site in p38[beta] compared with p38[alpha]</PubMed_Title>
      <Author>Patel, S.B., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of P38 in complex with biphenyl amide inhibitor</PDB_Title>
      <PDB_ID>2ZB0</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZB0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl- 1,3,4-oxadiazol-2-yl)-4
-biphenylcarboxamide $ GLYCEROL</Ligand_Name>
      <PubMed_Title>Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode</PubMed_Title>
      <Author>Angell RM, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Jan 1;18(1):318-23. Epub  2007 Nov 19.</Journal>
      <PubMed_ID>18006306</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR</PDB_Title>
      <PDB_ID>1W7H</PDB_ID>
      <Resolution>2.21</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W7H</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-(BENZYLOXY)PYRIDIN-2-AMINE</Ligand_Name>
      <PubMed_Title>Fragment-Based Lead Discovery Using X-Ray Crystallography</PubMed_Title>
      <Author>Hartshorn MJ, et al.</Author>
      <Journal>J Med Chem.2005 Jan 27;48(2):403-13.</Journal>
      <PubMed_ID>15658854</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 complex with a phthalazine inhibitor</PDB_Title>
      <PDB_ID>3DS6</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DS6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin- 6-yl]benzamide</Ligand_Name>
      <PubMed_Title>Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.</PubMed_Title>
      <Author>Herberich B, et al.</Author>
      <Journal>J Med Chem.2008 Oct 23;51(20):6271-9. Epub  2008 Sep 26.</Journal>
      <PubMed_ID>18817365</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of p38a Mitogen-Activated Protein Kinase in Complex with a Pyrazolopyridazine Inhibitor</PDB_Title>
      <PDB_ID>3ITZ</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ITZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-chloro-N-cyclopropyl-3-{[1-(2,6-difluorophenyl)- 1H-pyrazolo[3,4-d]pyridazin-4
-yl]amino}benzamide</Ligand_Name>
      <PubMed_Title>Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.</PubMed_Title>
      <Author>Wurz RP, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2010 Mar 1;20(5):1680-4. Epub  2010 Jan 21.</Journal>
      <PubMed_ID>20138761</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of MAP kinase p38 in complex with a 1-o-tolyl-1,2,3-triazole-4-carboxamide</PDB_Title>
      <PDB_ID>3CTQ</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CTQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-benzyl-1-[5-({5-tert-butyl-2-methoxy-3- [
(methylsulfonyl)amino]phenyl}carbamoyl)- 2-methylphenyl]-1H-1,2,3-triazole-4-carboxamide</Ligand_Name>
      <PubMed_Title>Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.</PubMed_Title>
      <Author>Cogan DA, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Jun 1;18(11):3251-5. Epub  2008 Apr 25.</Journal>
      <PubMed_ID>18462940</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11J</PDB_Title>
      <PDB_ID>2RG6</PDB_ID>
      <Resolution>1.72</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2RG6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}- 5-methyl-N-[(1S)-1
-phenylethyl]pyrrolo[2,1- f][1,2,4]triazine-6-carboxamide</Ligand_Name>
      <PubMed_Title>Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha Mitogen-Activated Protein Kinase Inhibitors</PubMed_Title>
      <Author>Hynes J Jr, et al.</Author>
      <Journal>J Med Chem.2008 Jan 10;51(1):4-16. Epub  2007 Dec 12.</Journal>
      <PubMed_ID>18072718</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state</PDB_Title>
      <PDB_ID>2PV8</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PV8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>3MH1: Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.</PubMed_Title>
      <Author>Bukhtiyarova, M., et al.</Author>
      <Journal>Biochemistry. 2007 May 15;46(19):5687-96. Epub 2007 Apr 19.</Journal>
      <PubMed_ID>17441692</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human p38alpha complexed with PH-797804</PDB_Title>
      <PDB_ID>3HLL</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HLL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6- methyl-2-oxopyridin-1(2H)-yl}-N,4
-dimethylbenzamide $ 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol- 3-yl]pyridine $ HYPOPHOSPHITE</Ligand_Name>
      <PubMed_Title>Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.</PubMed_Title>
      <Author>Xing L, et al.</Author>
      <Journal>Biochemistry.2009 Jul 14;48(27):6402-11.</Journal>
      <PubMed_ID>19496616</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with RO6226</PDB_Title>
      <PDB_ID>3FMM</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FMM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-N-[(1R)-1-methyl- 2-(methylsulfonyl)ethyl]-1H-pyrazolo
[3,4- d]pyrimidin-3-amine</Ligand_Name>
      <PubMed_Title>P38 kinase crystal structure in complex with RO6226</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state</PDB_Title>
      <PDB_ID>2PTO</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PTO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>3MH2: Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.</PubMed_Title>
      <Author>Bukhtiyarova, M., et al.</Author>
      <Journal>Biochemistry. 2007 May 15;46(19):5687-96. Epub 2007 Apr 19.</Journal>
      <PubMed_ID>17441692</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with pamapimod</PDB_Title>
      <PDB_ID>3FLW</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FLW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-2-{[3-hydroxy-1-(2- hydroxyethyl)propyl]amino}-8
-methylpyrido[2,3- d]pyrimidin-7(8H)-one</Ligand_Name>
      <PubMed_Title>The Discovery of Pamapimod, R1503 and R1487 as Orally Bioavailable and Highly Selective Inhibitors of p38 Map Kinase</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of P38 alpha in complex with DP437</PDB_Title>
      <PDB_ID>3NNV</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NNV</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490117</ASD_Ligand>
      <PubMed_Title>Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region</PubMed_Title>
      <Author>Ahn, Y.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:5793-5798</Journal>
      <PubMed_ID>20800479</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human P38 MAP kinase in complex with RL48</PDB_Title>
      <PDB_ID>3GCU</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GCU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03498002</ASD_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ 2-(N-MORPHOLINO)-ETHANESULFONIC ACID $ 1-{3-[(6-aminoquinazolin-4-yl)amino]phenyl}- 3-[3-tert-butyl-1-(4-methylphenyl)
-1H-pyrazol- 5-yl]urea 
-1H-pyrazol- 5-yl]urea</Ligand_Name>
      <PubMed_Title>Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2009 Sep 23;131(37):13286-96.</Journal>
      <PubMed_ID>19572644</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>p38alpha MAP kinase bound to MPAQ</PDB_Title>
      <PDB_ID>2BAK</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BAK</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490119</ASD_Ligand>
      <Ligand_Name>N-(3-{[7-METHOXY-6-(2-PYRROLIDIN-1-YLETHOXY)QUINAZOLIN- 4-YL]AMINO}-4
-METHYLPHENYL)-2-MORPHOLIN-4- YLISONICOTINAMIDE</Ligand_Name>
      <PubMed_Title>Prevention of MKK6-Dependent Activation by Binding to p38alpha MAP Kinase</PubMed_Title>
      <Author>Sullivan JE, et al.</Author>
      <Journal>Biochemistry.2005 Dec 20;44(50):16475-90.</Journal>
      <PubMed_ID>16342939</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.</PDB_Title>
      <PDB_ID>1WBS</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WBS</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490101</ASD_Ligand>
      <Ligand_Name>3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN- 4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE $ GLYCEROL</Ligand_Name>
      <PubMed_Title>Identification of Novel P38Alpha Map Kinase Inhibitors Using Fragment-Based Lead Generation.</PubMed_Title>
      <Author>Gill AL, et al.</Author>
      <Journal>J Med Chem.2005 Jan 27;48(2):414-26.</Journal>
      <PubMed_ID>15658855</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with RL49</PDB_Title>
      <PDB_ID>3HV3</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HV3</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490105</ASD_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ GLYCEROL $ 1-{4-[(6-aminoquinolin-4-yl)amino]phenyl}- 3-[3-tert-butyl-1-(3-methylphenyl)-1H
-pyrazol- 5-yl]urea</Ligand_Name>
      <PubMed_Title>Displacement assay for the detection of stabilizers of inactive kinase conformations.</PubMed_Title>
      <Author>Kluter, S., et al.</Author>
      <Journal>J Med Chem. 2010 Jan 14;53(1):357-67.</Journal>
      <PubMed_ID>19928858</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human P38 MAP kinase in complex with RL45</PDB_Title>
      <PDB_ID>3GCQ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GCQ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740016</ASD_Ligand>
      <Ligand_Name>1-{4-[(6-aminoquinazolin-4-yl)amino]phenyl}- 3-[3-tert-butyl-1-(3-methylphenyl)
-1H-pyrazol- 5-yl]urea $ B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2009 Sep 23;131(37):13286-96.</Journal>
      <PubMed_ID>19572644</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 in complex with Sorafenib</PDB_Title>
      <PDB_ID>3HEG</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HEG</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00450013</ASD_Ligand>
      <Ligand_Name>4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}- N
-METHYLPYRIDINE-2-CARBOXAMIDE</Ligand_Name>
      <PubMed_Title>Analysis of Imatinib and Sorafenib binding to p38 alpha compared with c-Abl and b-Raf provides structural insights into design of inhibitors targeting the DFG-out form of protein kinases</PubMed_Title>
      <Author>Namboodiri, H.V., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with R1487</PDB_Title>
      <PDB_ID>3FLN</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FLN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro- 2H-pyran-4-ylamino)pyrido[2,3
-d]pyrimidin- 7(8H)-one</Ligand_Name>
      <PubMed_Title>The Discovery of Pamapimod, R1503 and R1487 as Orally Bioavailable and Highly Selective Inhibitors of p38 Map Kinase</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with RO6257</PDB_Title>
      <PDB_ID>3FSK</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FSK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-(2-chlorophenyl)-7-[(trans-4-hydroxycyclohexyl)amino]- 3,4-dihydropyrimido[4,5
-d]pyrimidin-2(1H)- one</Ligand_Name>
      <PubMed_Title>Mapping Binding Pocket Volume: Potential Applications towards Ligand Design and Selectivity</PubMed_Title>
      <Author>Arora, N., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of P38 alpha in complex with DP1376</PDB_Title>
      <PDB_ID>3NNU</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NNU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490124</ASD_Ligand>
      <PubMed_Title>Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region</PubMed_Title>
      <Author>Ahn, Y.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:5793-5798</Journal>
      <PubMed_ID>20800479</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with RL182</PDB_Title>
      <PDB_ID>3PG3</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PG3</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03492011</ASD_Ligand>
      <PubMed_Title>Structure-based design and synthesis of cell active N-pyrazole, N-thiazole urea inhibitors of the MAP kinase p38alpha</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Mutagenesis of p38 MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state</PDB_Title>
      <PDB_ID>2PTJ</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PTJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>3MH3: Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.</PubMed_Title>
      <Author>Bukhtiyarova, M., et al.</Author>
      <Journal>Biochemistry. 2007 May 15;46(19):5687-96. Epub 2007 Apr 19.</Journal>
      <PubMed_ID>17441692</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>p38alpha MAP kinase bound to pyrazoloamine</PDB_Title>
      <PDB_ID>2BAL</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BAL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4- YL][3-(PIPERIDIN-4
-YLOXY)PHENYL]METHANONE</Ligand_Name>
      <PubMed_Title>Prevention of MKK6-Dependent Activation by Binding to p38alpha MAP Kinase.</PubMed_Title>
      <Author>Sullivan JE, et al.</Author>
      <Journal>Biochemistry.2005 Dec 20;44(50):16475-90.</Journal>
      <PubMed_ID>16342939</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human P38 MAP Kinase in Complex with SB203580</PDB_Title>
      <PDB_ID>3GCP</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GCP</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490016</ASD_Ligand>
      <Ligand_Name>4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL- PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE $ B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2009 Sep 23;131(37):13286-96.</Journal>
      <PubMed_ID>19572644</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of P38 Kinase in Complex with a biphenyl amide inhibitor</PDB_Title>
      <PDB_ID>3D7Z</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3D7Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)- 6-methylbiphenyl-3,4'-dicarboxamide $ GLYCEROL $ SULFATE ION</Ligand_Name>
      <PubMed_Title>Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.</PubMed_Title>
      <Author>Angell R, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Aug 1;18(15):4428-32. Epub  2008 Jun 18.</Journal>
      <PubMed_ID>18614366</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-6,7-DIMETHOXYQUINAZOLINE</PDB_Title>
      <PDB_ID>1DI9</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DI9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-[3-METHYLSULFANYLANILINO]-6,7-DIMETHOXYQUINAZOLINE</Ligand_Name>
      <PubMed_Title>Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase.</PubMed_Title>
      <Author>Shewchuk L, et al.</Author>
      <Journal>J Med Chem.2000 Jan 13;43(1):133-8.</Journal>
      <PubMed_ID>10633045</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>p38a-PIA23 complex</PDB_Title>
      <PDB_ID>4E6A</PDB_ID>
      <Resolution>2.09</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4E6A</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490132</ASD_Ligand>
      <PubMed_Title>Lipid Molecules Induce p38 alpha Activation via a Novel Molecular Switch.</PubMed_Title>
      <Author>Tzarum, N., et al.</Author>
      <Journal>J.Mol.Biol.(2012)424:339-353</Journal>
      <PubMed_ID>23079240</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of P38 Kinase in Complex with A Biaryl Amide Inhibitor</PDB_Title>
      <PDB_ID>3E93</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E93</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490099</ASD_Ligand>
      <Ligand_Name>4-methyl-N-(3-morpholin-4-ylphenyl)-3-(3- piperidin-4-yl-1,2-benzisoxazol-6
-yl)benzamide $ GLYCEROL</Ligand_Name>
      <PubMed_Title>Kinase array design, back to front: Biaryl amides</PubMed_Title>
      <Author>Baldwin I, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Oct 1;18(19):5285-9. Epub  2008 Aug 22.</Journal>
      <PubMed_ID>18789685</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-8-methyl-2-((S)-1-methyl-2-tetrazol-2-yl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one</PDB_Title>
      <PDB_ID>3FMK</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FMK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-8-methyl-2-{[(1S)- 1-methyl-2-(2H-tetrazol-2
-yl)ethyl]amino}pyrido[2,3- d]pyrimidin-7(8H)-one</Ligand_Name>
      <PubMed_Title>The Discovery of Pamapimod and R1487 as Orally Bioavailable and Highly Selective Inhibitors of p38 Map Kinase</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex WITH 8-Methyl-6-phenoxy-2-(tetrahydro-pyran-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one</PDB_Title>
      <PDB_ID>3FLZ</PDB_ID>
      <Resolution>2.23</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FLZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>8-methyl-6-phenoxy-2-(tetrahydro-2H-pyran- 4-ylamino)pyrido[2,3-d]pyrimidin-7
(8H)-one</Ligand_Name>
      <PubMed_Title>The Discovery of Pamapimod and R1487 as Orally Bioavailable and Highly Selective Inhibitors of p38 Map Kinase</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1-methyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one</PDB_Title>
      <PDB_ID>3FSF</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FSF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-(2,6-dichlorophenyl)-7-({4-[(diethylamino)methoxy]phenyl}amino)- 1-methyl-3,4
-dihydropyrimido[4,5-d]pyrimidin- 2(1H)-one</Ligand_Name>
      <PubMed_Title>The Discovery of Pamapimod and R1487 as Orally Bioavailable and Highly Selective Inhibitors of p38 Map Kinase</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR</PDB_Title>
      <PDB_ID>1W83</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W83</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490096</ASD_Ligand>
      <Ligand_Name>N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]- 3-FLUORO-</Ligand_Name>
      <PubMed_Title>Identification of Novel P38Alpha Map Kinase Inhibitors Using Fragment-Based Lead Generation</PubMed_Title>
      <Author>Gill AL, et al.</Author>
      <Journal>J Med Chem.2005 Jan 27;48(2):414-26.</Journal>
      <PubMed_ID>15658855</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>p38alpha bound to Ro3201195</PDB_Title>
      <PDB_ID>2BAQ</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BAQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4- YL](3-{[(2R)-2,3
-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE</Ligand_Name>
      <PubMed_Title>Prevention of MKK6-Dependent Activation by Binding to p38alpha MAP Kinase.</PubMed_Title>
      <Author>Sullivan JE, et al.</Author>
      <Journal>Biochemistry.2005 Dec 20;44(50):16475-90.</Journal>
      <PubMed_ID>16342939</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>mitogen activated protein kinase p38alpha (D176A+F327S) activating mutant form-B</PDB_Title>
      <PDB_ID>2FSM</PDB_ID>
      <Resolution>1.86</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FSM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Structures of p38alpha Active Mutants Reveal Conformational Changes in L16 Loop that Induce Autophosphorylation and Activation</PubMed_Title>
      <Author>Diskin R, et al.</Author>
      <Journal>J Mol Biol.2007 Jan 5;365(1):66-76. Epub  2006 Aug 22.</Journal>
      <PubMed_ID>17059827</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580</PDB_Title>
      <PDB_ID>1A9U</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1A9U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL- PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE</Ligand_Name>
      <PubMed_Title>Structural basis of inhibitor selectivity in MAP kinases.</PubMed_Title>
      <Author>Wang Z, et al.</Author>
      <Journal>Structure.1998 Sep 15;6(9):1117-28.</Journal>
      <PubMed_ID>9753691</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with an Imidazo-pyridine</PDB_Title>
      <PDB_ID>3IW7</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IW7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ 2-({4-[(4-benzylpiperidin-1-yl)carbonyl]benzyl}sulfanyl)- 3H-imidazo[4,5
-c]pyridine</Ligand_Name>
      <PubMed_Title>High-Throughput Screening To Identify Inhibitors Which Stabilize Inactive Kinase Conformations in p38alpha</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2009 Dec 30;131(51):18478-88.</Journal>
      <PubMed_ID>19950957</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of p38 MAP kinase in complex with a dihydroquinazolinone inhibitor</PDB_Title>
      <PDB_ID>1M7Q</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1M7Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1-(2,6-DICHLOROPHENYL)-5-(2,4-DIFLUOROPHENYL)- 7-PIPERAZIN-1-YL-3,4
-DIHYDROQUINAZOLIN-2(1H)- ONE $ SULFATE ION</Ligand_Name>
      <PubMed_Title>Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.</PubMed_Title>
      <Author>Stelmach JE, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2003 Jan 20;13(2):277-80.</Journal>
      <PubMed_ID>12482439</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human p38alpha Complexed With a Triazolopyrimidine compound</PDB_Title>
      <PDB_ID>3KF7</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KF7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-{6-[2-(2,4-difluorophenyl)ethyl][1,2,4]triazolo[4,3- a]pyridin-3-yl}-4
-methylbenzamide</Ligand_Name>
      <PubMed_Title>Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition.</PubMed_Title>
      <Author>Jerome KD, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2010 Jan 15;20(2):469-73. Epub  2009 Nov 26.</Journal>
      <PubMed_ID>19969459</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the P38a-MAPKAP kinase 2 Heterodimer</PDB_Title>
      <PDB_ID>2OKR</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OKR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Crystal structure of the P38alpha-MAPKAP kinase 2 heterodimer.</PubMed_Title>
      <Author>ter Haar E, et al.</Author>
      <Journal>J Biol Chem.2007 Mar 30;282(13):9733-9. Epub  2007 Jan 25.</Journal>
      <PubMed_ID>17255097</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with RL40</PDB_Title>
      <PDB_ID>3HUC</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HUC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ N-[2-phenyl-4-(1H-pyrazol-3-ylamino)quinazolin- 7-yl]prop-2-enamide $ 2-(N-MORPHOLINO)-ETHANESULFONIC ACID</Ligand_Name>
      <PubMed_Title>Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2010 Mar 31;132(12):4152-60.</Journal>
      <PubMed_ID>20201574</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of p38 in complex with a biphenylamide inhibitor</PDB_Title>
      <PDB_ID>3IPH</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IPH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-[5-(cyclopropylcarbamoyl)-2-methylphenyl]- N-(cyclopropylmethyl)pyridine-3
-carboxamide $ GLYCEROL $ SULFATE ION</Ligand_Name>
      <PubMed_Title>p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.</PubMed_Title>
      <Author>Aston NM, et al.</Author>
      <Journal>J Med Chem.2009 Oct 22;52(20):6257-69.</Journal>
      <PubMed_ID>19772287</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR</PDB_Title>
      <PDB_ID>1W82</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W82</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490108</ASD_Ligand>
      <Ligand_Name>N-[(3Z)-5-TERT-BUTYL-2-PHENYL-1,2-DIHYDRO- 3H-PYRAZOL-3-YLIDENE]-N'-(4
-CHLOROPHENYL)UREA</Ligand_Name>
      <PubMed_Title>Identification of Novel P38Alpha Map Kinase Inhibitors Using Fragment-Based Lead Generation</PubMed_Title>
      <Author>Gill AL, et al.</Author>
      <Journal>J Med Chem.2005 Jan 27;48(2):414-26.</Journal>
      <PubMed_ID>15658855</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of phosphorylated P38 alpha in complex with DP802</PDB_Title>
      <PDB_ID>3NNX</PDB_ID>
      <Resolution>2.28</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NNX</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490125</ASD_Ligand>
      <PubMed_Title>Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region</PubMed_Title>
      <Author>Ahn, Y.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:5793-5798</Journal>
      <PubMed_ID>20800479</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human p38alpha complexed with a pyridinone compound</PDB_Title>
      <PDB_ID>3HP2</PDB_ID>
      <Resolution>2.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HP2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol- 3-yl]pyridine $ 1-benzyl-4-(benzyloxy)-3-bromopyridin-2(1H)- one</Ligand_Name>
      <PubMed_Title>Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.</PubMed_Title>
      <Author>Selness SR, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2009 Oct 15;19(20):5851-6. Epub  2009 Aug 27.</Journal>
      <PubMed_ID>19751974</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with RL51</PDB_Title>
      <PDB_ID>3HV4</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HV4</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490115</ASD_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ 1-{3-[(6-aminoquinolin-4-yl)amino]phenyl}- 3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol- 5-yl]urea $ 2-(N-MORPHOLINO)-ETHANESULFONIC ACID</Ligand_Name>
      <PubMed_Title>Displacement assay for the detection of stabilizers of inactive kinase conformations.</PubMed_Title>
      <Author>Kluter, S., et al.</Author>
      <Journal>J Med Chem. 2010 Jan 14;53(1):357-67.</Journal>
      <PubMed_ID>19928858</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11B</PDB_Title>
      <PDB_ID>2RG5</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2RG5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}- 5-methylpyrrolo[2,1-f]
[1,2,4]triazine-6-carboxamide</Ligand_Name>
      <PubMed_Title>Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha Mitogen-Activated Protein Kinase Inhibitors</PubMed_Title>
      <Author>Hynes J Jr, et al.</Author>
      <Journal>J Med Chem.2008 Jan 10;51(1):4-16. Epub  2007 Dec 12.</Journal>
      <PubMed_ID>18072718</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 Kinase Crystal Structure in complex with RO3201195</PDB_Title>
      <PDB_ID>2GFS</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2GFS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4- YL](3-{[(2R)-2,3
-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE</Ligand_Name>
      <PubMed_Title>Discovery of S-[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]-methanone (RO3201195), and Orally Bioavailable and Highly Selective Inhibitor of p38 Map Kinase</PubMed_Title>
      <Author>Goldstein DM, et al.</Author>
      <Journal>J Med Chem.2006 Mar 9;49(5):1562-75.</Journal>
      <PubMed_ID>16509574</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>p38 kinase Crystal structure in complex with small molecule inhibitor</PDB_Title>
      <PDB_ID>3HRB</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HRB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>[3-amino-2-(2-methylphenyl)-1-oxidopyridin- 4-yl](2,4-difluorophenyl)methanone</Ligand_Name>
      <PubMed_Title>Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase</PubMed_Title>
      <Author>Lumeras W, et al.</Author>
      <Journal>J Med Chem.2009 Sep 10;52(17):5531-45.</Journal>
      <PubMed_ID>19678708</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of p38 alpha in complex with a dihydropyrido-pyrimidine inhibitor</PDB_Title>
      <PDB_ID>1OUY</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OUY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1-(2,6-DICHLOROPHENYL)-6-[(2,4-DIFLUOROPHENYL)SULFANYL]- 7-(1,2,3,6-TETRAHYDRO-4
-PYRIDINYL)-3,4-DIHYDROPYRIDO[3,2- D]PYRIMIDIN-2(1H)-ONE</Ligand_Name>
      <PubMed_Title>Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity</PubMed_Title>
      <Author>Fitzgerald CE, et al.</Author>
      <Journal>Nat Struct Biol.2003 Sep;10(9):764-9. Epub  2003 Aug 3.</Journal>
      <PubMed_ID>12897767</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)-2-((s)-2-methanesulfonyl-1-methyl-ethylamino)-8-methyl-8h-pyrido[2,3-d]pyrimidin</PDB_Title>
      <PDB_ID>3FLQ</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FLQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-8-methyl-2-{[(1S)- 1-methyl-2-
(methylsulfonyl)ethyl]amino}pyrido[2,3- d]pyrimidin-7(8H)-one</Ligand_Name>
      <PubMed_Title>The Discovery of Pamapimod, R1503 and R1487 as Orally Bioavailable and Highly Selective Inhibitors of p38 Map Kinase</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with CP-547632</PDB_Title>
      <PDB_ID>3L8S</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L8S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-[(4-bromo-2,6-difluorobenzyl)oxy]-5-{[(4- pyrrolidin-1
-ylbutyl)carbamoyl]amino}isothiazole- 4-carboxamide $ B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2010 Mar 31;132(12):4152-60.</Journal>
      <PubMed_ID>20201574</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with RO6224</PDB_Title>
      <PDB_ID>3FML</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FML</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-N-[(1S)-1-methyl- 2-(methylsulfonyl)ethyl]-1H-pyrazolo
[3,4- d]pyrimidin-3-amine</Ligand_Name>
      <PubMed_Title>P38 kinase crystal structure in complex with RO6224</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.</PDB_Title>
      <PDB_ID>1WBW</PDB_ID>
      <Resolution>2.41</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WBW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE</Ligand_Name>
      <PubMed_Title>Identification of Novel P38Alpha Map Kinase Inhibitors Using Fragment-Based Lead Generation</PubMed_Title>
      <Author>Gill AL, et al.</Author>
      <Journal>J Med Chem.2005 Jan 27;48(2):414-26.</Journal>
      <PubMed_ID>15658855</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the p38a-MAPKAP kinase 2 Heterodimer</PDB_Title>
      <PDB_ID>2ONL</PDB_ID>
      <Resolution>4.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ONL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Crystal structure of the P38alpha-MAPKAP kinase 2 heterodimer.</PubMed_Title>
      <Author>ter Haar E, et al.</Author>
      <Journal>J Biol Chem.2007 Mar 30;282(13):9733-9. Epub  2007 Jan 25.</Journal>
      <PubMed_ID>17255097</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of p38 alpha in complex with a dihydroquinolinone</PDB_Title>
      <PDB_ID>1OVE</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OVE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1-(2,6-DICHLOROPHENYL)-5-(2,4-DIFLUOROPHENYL)- 7-PIPERIDIN-4-YL-3,4
-DIHYDROQUINOLIN-2(1H)- ONE $ GLYCEROL</Ligand_Name>
      <PubMed_Title>Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity</PubMed_Title>
      <Author>Fitzgerald CE, et al.</Author>
      <Journal>Nat Struct Biol.2003 Sep;10(9):764-9. Epub  2003 Aug 3.</Journal>
      <PubMed_ID>12897767</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding</PDB_Title>
      <PDB_ID>3O8P</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3O8P</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740008</ASD_Ligand>
      <PubMed_Title>Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of P38 with triazolopyridine</PDB_Title>
      <PDB_ID>1ZZL</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZZL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-[4-(4-FLUOROPHENYL)-1,3-OXAZOL-5-YL]-3- ISOPROPYL[1,2,4]TRIAZOLO[4,3
-A]PYRIDINE</Ligand_Name>
      <PubMed_Title>Theoretical and Experimental Design of Atypical Kinase Inhibitors: Application to p38 MAP Kinase.</PubMed_Title>
      <Author>McClure KF, et al.</Author>
      <Journal>J Med Chem.2005 Sep 8;48(18):5728-37.</Journal>
      <PubMed_ID>16134941</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of Inactive Human p38 MAP Kinase in Complex with a Thiazole-Urea</PDB_Title>
      <PDB_ID>3IW8</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IW8</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490103</ASD_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ 1-{4-[(1S)-1-amino-2-(benzyloxy)ethyl]-1,3- thiazol-2-yl}-3-(3-chloro-4
-fluorophenyl)urea</Ligand_Name>
      <PubMed_Title>High-Throughput Screening To Identify Inhibitors Which Stabilize Inactive Kinase Conformations in p38alpha</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2009 Dec 30;131(51):18478-88.</Journal>
      <PubMed_ID>19950957</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of P38 in complex with biphenyl amide inhibitor</PDB_Title>
      <PDB_ID>2ZB1</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZB1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl- 1,3,4-oxadiazol-2-yl)biphenyl-4
-carboxamide $ GLYCEROL</Ligand_Name>
      <PubMed_Title>Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode</PubMed_Title>
      <Author>Angell RM, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Jan 1;18(1):318-23. Epub  2007 Nov 19.</Journal>
      <PubMed_ID>18006306</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Mutagenesis of p38 MAP Kinase eshtablishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-out state</PDB_Title>
      <PDB_ID>2PV5</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PV5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>3MGY: Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.</PubMed_Title>
      <Author>Bukhtiyarova, M., et al.</Author>
      <Journal>Biochemistry. 2007 May 15;46(19):5687-96. Epub 2007 Apr 19.</Journal>
      <PubMed_ID>17441692</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with RO9552</PDB_Title>
      <PDB_ID>3FKL</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FKL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N-cyclopropyl-4-methyl-3-[8-methyl-7-oxo- 2-(tetrahydro-2H-pyran-4-ylamino)-7,8
-dihydropyrido[2,3- d]pyrimidin-6-yl]benzamide</Ligand_Name>
      <PubMed_Title>Mapping Binding Pocket Volume: Potential Applications towards Ligand Design and Selectivity</PubMed_Title>
      <Author>Arora, N., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with RL116</PDB_Title>
      <PDB_ID>3LFE</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LFE</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03492010</ASD_Ligand>
      <PubMed_Title>Development of novel thiazole-urea compounds which stabalize the inactive conformation of p38 alpha</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>p38 MAP Kinase in Complex with Inhibitor 1</PDB_Title>
      <PDB_ID>1KV1</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KV1</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740008</ASD_Ligand>
      <Ligand_Name>1-(5-TERT-BUTYL-2-METHYL-2H-PYRAZOL-3-YL)- 3-(4-CHLORO-PHENYL)-UREA</Ligand_Name>
      <PubMed_Title>Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.</PubMed_Title>
      <Author>Pargellis C, et al.</Author>
      <Journal>Nat Struct Biol.2002 Apr;9(4):268-72.</Journal>
      <PubMed_ID>11896401</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE STRUCTURE OF P38ALPHA C162S MUTANT</PDB_Title>
      <PDB_ID>1R3C</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1R3C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>MAGNESIUM ION</Ligand_Name>
      <PubMed_Title>Lattice stabilization and enhanced diffraction in human p38 alpha crystals by protein engineering.</PubMed_Title>
      <Author>Patel SB, et al.</Author>
      <Journal>Biochim Biophys Acta.2004 Jan 14;1696(1):67-73.</Journal>
      <PubMed_ID>14726206</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human P38 MAP Kinase in Complex with RL62</PDB_Title>
      <PDB_ID>3GCV</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GCV</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740019</ASD_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ 1-{3-[(6-aminoquinazolin-4-yl)amino]phenyl}- 3-[3-tert-butyl-1-(3-methylphenyl)
-1H-pyrazol- 5-yl]urea</Ligand_Name>
      <PubMed_Title>Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2009 Sep 23;131(37):13286-96.</Journal>
      <PubMed_ID>19572644</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding</PDB_Title>
      <PDB_ID>3O8U</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3O8U</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740008</ASD_Ligand>
      <PubMed_Title>Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with 6-(2,4-Difluoro-phenoxy)-2-((R)-2-methanesulfonyl-1-methyl-ethylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one</PDB_Title>
      <PDB_ID>3FLS</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FLS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-8-methyl-2-{[(1R)- 1-methyl-2-
(methylsulfonyl)ethyl]amino}pyrido[2,3- d]pyrimidin-7(8H)-one</Ligand_Name>
      <PubMed_Title>The Discovery of Pamapimod, R1503 and R1487 as Orally Bioavailable and Highly Selective Inhibitors of p38 Map Kinase</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38alpha bound to novel DFG-out compound PF-00416121</PDB_Title>
      <PDB_ID>3K3J</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3K3J</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490113</ASD_Ligand>
      <Ligand_Name>2-(4-fluorophenyl)-3-oxo-6-pyridin-4-yl-N- [2-(trifluoromethyl)benzyl]-2,3
-dihydropyridazine- 4-carboxamide $ 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol- 3-yl]pyridine</Ligand_Name>
      <PubMed_Title>The Design, Synthesis and Potential Utility of Fluorescence Probes that Target DFG-out Conformation of p38alpha for High Throughput Screening Binding Assay.</PubMed_Title>
      <Author>Tecle H, et al.</Author>
      <Journal>Chem Biol Drug Des.2009 Dec;74(6):547-59. Epub  2009 Oct 20.</Journal>
      <PubMed_ID>19843080</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human p38alpha complexed with a pyrimidopyridazinone compound</PDB_Title>
      <PDB_ID>3HP5</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HP5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]- 6H-pyrimido[1,6
-b]pyridazin-6-one $ 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol- 3-yl]pyridine</Ligand_Name>
      <PubMed_Title>Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.</PubMed_Title>
      <Author>Selness SR, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2009 Oct 15;19(20):5851-6. Epub  2009 Aug 27.</Journal>
      <PubMed_ID>19751974</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of P38 alpha in complex with DP802</PDB_Title>
      <PDB_ID>3NNW</PDB_ID>
      <Resolution>1.89</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NNW</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490125</ASD_Ligand>
      <PubMed_Title>Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region</PubMed_Title>
      <Author>Ahn, Y.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:5793-5798</Journal>
      <PubMed_ID>20800479</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human p38 MAP Kinase in Complex with an Indole Derivative</PDB_Title>
      <PDB_ID>3IW5</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IW5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ N-[2-(3-{[2-(2,3-dihydro-1,4-benzodioxin- 6-ylamino)-2-oxoethyl]sulfanyl}-1H
-indol- 1-yl)ethyl]-3-(trifluoromethyl)benzamide 
-carboxylate</Ligand_Name>
      <PubMed_Title>High-Throughput Screening To Identify Inhibitors Which Stabilize Inactive Kinase Conformations in p38alpha</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2009 Dec 30;131(51):18478-88.</Journal>
      <PubMed_ID>19950957</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FRAGMENT BASED P38 INHIBITORS</PDB_Title>
      <PDB_ID>1WBO</PDB_ID>
      <Resolution>2.16</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WBO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2-CHLOROPHENOL</Ligand_Name>
      <PubMed_Title>Fragment-Based Lead Discovery Using X-Ray Crystallography</PubMed_Title>
      <Author>Hartshorn MJ, et al.</Author>
      <Journal>J Med Chem.2005 Jan 27;48(2):403-13.</Journal>
      <PubMed_ID>15658854</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The crystal structure of p38a MAP kinase in complex with PIA24</PDB_Title>
      <PDB_ID>4E8A</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4E8A</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490130</ASD_Ligand>
      <PubMed_Title>Lipid Molecules Induce p38 alpha Activation via a Novel Molecular Switch.</PubMed_Title>
      <Author>Tzarum, N., et al.</Author>
      <Journal>J.Mol.Biol.(2012)424:339-353</Journal>
      <PubMed_ID>23079240</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 alpha kinase complexed with a pyrazolo-pyrimidine based inhibitor</PDB_Title>
      <PDB_ID>3L8X</PDB_ID>
      <Resolution>2.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L8X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4- d]pyrimidin-4-yl)amino]benzamide</Ligand_Name>
      <PubMed_Title>Pyrazolo-Pyrimidines: A Novel Heterocyclic Scaffold for Potent and Selective P38 Alpha Inhibitors.</PubMed_Title>
      <Author>Das J, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Apr 15;18(8):2652-7. Epub  2008 Mar 10.</Journal>
      <PubMed_ID>18359226</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of P38 kinase in complex with a biphenyl amide inhibitor</PDB_Title>
      <PDB_ID>3D83</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3D83</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490098</ASD_Ligand>
      <Ligand_Name>N-{4'-[(cyclopropylmethyl)carbamoyl]-6-methylbiphenyl- 3-yl}-2-morpholin-4
-ylpyridine-4-carboxamide $ GLYCEROL</Ligand_Name>
      <PubMed_Title>Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.</PubMed_Title>
      <Author>Angell RM, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Aug 1;18(15):4433-7. Epub  2008 Jun 12.</Journal>
      <PubMed_ID>18602262</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human P38 MAP kinase in complex with Sorafenib</PDB_Title>
      <PDB_ID>3GCS</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GCS</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00450013</ASD_Ligand>
      <Ligand_Name>4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}- N
-METHYLPYRIDINE-2-CARBOXAMIDE $ B-OCTYLGLUCOSIDE</Ligand_Name>
      <PubMed_Title>Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>J Am Chem Soc.2009 Sep 23;131(37):13286-96.</Journal>
      <PubMed_ID>19572644</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 ALPHA map kinase complexed with a benzothiazole based inhibitor</PDB_Title>
      <PDB_ID>3C5U</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3C5U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N- (1-methylethyl)-1,3-benzothiazol-2
-amine</Ligand_Name>
      <PubMed_Title>Benzothiazole based inhibitors of p38alpha MAP kinase.</PubMed_Title>
      <Author>Liu C, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Mar 15;18(6):1874-9. Epub  2008 Feb 10.</Journal>
      <PubMed_ID>18296051</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with 4-(5-Methyl-3-phenyl-isoxazol-4-yl)-pyrimidin-2-ylamine</PDB_Title>
      <PDB_ID>3FMJ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FMJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>4-(5-methyl-3-phenylisoxazol-4-yl)pyrimidin- 2-amine</Ligand_Name>
      <PubMed_Title>The Discovery of Pamapimod and R1487 as Orally Bioavailable and Highly Selective Inhibitors of p38 Map Kinase</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding</PDB_Title>
      <PDB_ID>3OC1</PDB_ID>
      <Resolution>2.59</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OC1</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740008</ASD_Ligand>
      <PubMed_Title>Conformational plasticity of p38 MAP kinase DFG motif mutants in response to inhibitor binding</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>P38 Alpha Map Kinase inhibitor based on heterobicyclic scaffolds</PDB_Title>
      <PDB_ID>2QD9</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QD9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1-[(3AR)-5-{[3-(2,4-DIFLUOROPHENYL)-5,6-DIHYDROIMIDAZO[1,5- A]PYRAZIN-7(8H)
-YL]CARBONYL}-6-METHOXY-3AH- PYRROLO[2,3-B]PYRIDIN-3-YL]-2-[(3R)-3-HYDROXYPYRROLIDIN
- 1-YL]-2-OXOETHANONE</Ligand_Name>
      <PubMed_Title>Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds.</PubMed_Title>
      <Author>Murali Dhar TG, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2007 Sep 15;17(18):5019-24. Epub  2007 Jul 21.</Journal>
      <PubMed_ID>17664068</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>p38alpha bound to novel DGF-out compound PF-00215955</PDB_Title>
      <PDB_ID>3K3I</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3K3I</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03490095</ASD_Ligand>
      <Ligand_Name>(3S)-3-[4-(4-bromophenyl)-1H-imidazol-2-yl]- 1,2,3,4-tetrahydroisoquinoline $ 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol- 3-yl]pyridine</Ligand_Name>
      <PubMed_Title>The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.</PubMed_Title>
      <Author>Tecle H, et al.</Author>
      <Journal>Chem Biol Drug Des.2009 Dec;74(6):547-59. Epub  2009 Oct 20.</Journal>
      <PubMed_ID>19843080</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 in complex with Imatinib</PDB_Title>
      <PDB_ID>3HEC</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HEC</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740007</ASD_Ligand>
      <Ligand_Name>B-OCTYLGLUCOSIDE $ 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL- 3-(4-PYRIDIN-3-YL-PYRIMIDIN-2
-YLAMINO)-PHENYL]- BENZAMIDE</Ligand_Name>
      <PubMed_Title>Analysis of Imatinib and Sorafenib binding in p38 alpha compared with c-Abl and B-Raf provides structural insights into design of inhibitors targeting the DFG-out form of protein kinases</PubMed_Title>
      <Author>Namboodiri, H.V., et al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>P38 kinase crystal structure in complex with RO2530</PDB_Title>
      <PDB_ID>3FMN</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FMN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>6-(2,4-difluorophenoxy)-N-(tetrahydro-2H- pyran-4-yl)-1H-pyrazolo[3,4
-d]pyrimidin-3- amine</Ligand_Name>
      <PubMed_Title>P38 kinase crystal structure in complex with RO2530</PubMed_Title>
      <Author>Soth, M., et.al.</Author>
      <Journal>To be Published</Journal>
      <PubMed_ID>Not in PubMed</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04622</Pathway_ID>
      <Pathway_Title>RIG-I-like receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04668</Pathway_ID>
      <Pathway_Title>TNF signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04620</Pathway_ID>
      <Pathway_Title>Toll-like receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04660</Pathway_ID>
      <Pathway_Title>T cell receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04723</Pathway_ID>
      <Pathway_Title>Retrograde endocannabinoid signaling</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Nervous system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04015</Pathway_ID>
      <Pathway_Title>Rap1 signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05014</Pathway_ID>
      <Pathway_Title>Amyotrophic lateral sclerosis (ALS)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Neurodegenerative diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04914</Pathway_ID>
      <Pathway_Title>Progesterone-mediated oocyte maturation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04723</Pathway_ID>
      <Pathway_Title>Retrograde endocannabinoid signaling</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Nervous system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05140</Pathway_ID>
      <Pathway_Title>Leishmaniasis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04670</Pathway_ID>
      <Pathway_Title>Leukocyte transendothelial migration</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04370</Pathway_ID>
      <Pathway_Title>VEGF signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04261</Pathway_ID>
      <Pathway_Title>Adrenergic signaling in cardiomyocytes</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Circulatory system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04912</Pathway_ID>
      <Pathway_Title>GnRH signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05160</Pathway_ID>
      <Pathway_Title>Hepatitis C</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05142</Pathway_ID>
      <Pathway_Title>Chagas disease (American trypanosomiasis)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05164</Pathway_ID>
      <Pathway_Title>Influenza A</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04722</Pathway_ID>
      <Pathway_Title>Neurotrophin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Nervous system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05145</Pathway_ID>
      <Pathway_Title>Toxoplasmosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04380</Pathway_ID>
      <Pathway_Title>Osteoclast differentiation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Development</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04917</Pathway_ID>
      <Pathway_Title>Prolactin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04668</Pathway_ID>
      <Pathway_Title>TNF signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04750</Pathway_ID>
      <Pathway_Title>Inflammatory mediator regulation of TRP channels</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Sensory system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04611</Pathway_ID>
      <Pathway_Title>Platelet activation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05169</Pathway_ID>
      <Pathway_Title>Epstein-Barr virus infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04621</Pathway_ID>
      <Pathway_Title>NOD-like receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05131</Pathway_ID>
      <Pathway_Title>Shigellosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05120</Pathway_ID>
      <Pathway_Title>Epithelial cell signaling in Helicobacter pylori infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05133</Pathway_ID>
      <Pathway_Title>Pertussis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04010</Pathway_ID>
      <Pathway_Title>MAPK signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04011</Pathway_ID>
      <Pathway_Title>MAPK signaling pathway - yeast</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04728</Pathway_ID>
      <Pathway_Title>Dopaminergic synapse</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Nervous system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04664</Pathway_ID>
      <Pathway_Title>Fc epsilon RI signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05152</Pathway_ID>
      <Pathway_Title>Tuberculosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04550</Pathway_ID>
      <Pathway_Title>Signaling pathways regulating pluripotency of stem cells</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04068</Pathway_ID>
      <Pathway_Title>FoxO signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04071</Pathway_ID>
      <Pathway_Title>Sphingolipid signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05132</Pathway_ID>
      <Pathway_Title>Salmonella infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.e.daa.b.b.f.html</SCOP_URL>
    <CATH_Class>Mixed alpha-beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1a9u</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,71,Glu;site,53,Lys;site,109,Met;motif,Asp-Phe-Gly(DFG) motif</Site_Detail>
      <Site_Reference>Pargellis C, et al. Nat.Struct.Biol. 2002,9(4):268-272.</Site_Reference>
      <Site_Type>Unknown</Site_Type>
      <PDB_ID>1KV1;1KV2;3GCP</PDB_ID>
      <PubMed_ID>11896401</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.11.24</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/11/24.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00450013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490017</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490018</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490020</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490021</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490022</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490023</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490024</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490025</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490026</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490028</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490029</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490030</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490031</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490032</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490033</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490034</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490035</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490036</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490037</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490038</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490039</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490040</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490041</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490042</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490043</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490044</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490045</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490046</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490047</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490048</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490049</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490050</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490051</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490052</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490053</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490054</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490055</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490056</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490057</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490058</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490059</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490060</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490061</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490062</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490063</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490064</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490065</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490066</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490067</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490068</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490069</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490070</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490071</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490072</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490073</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490074</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490075</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490076</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490077</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490078</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490079</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490080</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490081</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490082</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490083</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490084</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490085</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490086</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490094</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490095</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490096</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490097</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490098</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490099</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490101</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490102</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490103</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490105</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490106</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490108</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490109</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490113</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490114</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490115</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490117</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490118</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490119</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490122</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490123</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490124</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490125</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490130</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490131</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490132</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490133</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03490134</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491017</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491018</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03491020</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03492016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03498001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03498002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03498003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03498004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03498005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>